Favorable vaccine-induced SARS-CoV-2 specific T cell response profile in patients undergoing immune-modifying therapies

Martin Qui; Nina Le Bert; Webber Pak Wo Chan; Malcolm Tan; Shou Kit Hang; Smrithi Hariharaputran; Jean Xiang Ying Sim; Jenny Guek Hong Low; Weiling Ng; Wei Yee Wan; Tiing Leong Ang; Antonio Bertoletti; Ennaliza Salazar

doi:10.1172/JCI159500

Favorable vaccine-induced SARS-CoV-2 specific T cell response profile in patients undergoing immune-modifying therapies

Martin Qui,¹ Nina Le Bert,¹ Webber Pak Wo Chan,² Malcolm Tan,² Shou Kit Hang,¹ Smrithi Hariharaputran,¹ Jean Xiang Ying Sim,³ Jenny Guek Hong Low,³ Weiling Ng,⁴ Wei Yee Wan,⁴ Tiing Leong Ang,⁵ Antonio Bertoletti,¹ and Ennaliza Salazar²

Published May 10, 2022 - More info

View PDF

Abstract

BACKGROUND. Patients undergoing immune-modifying therapies demonstrate a reduced humoral response after COVID-19 vaccination, but we lack a proper evaluation of the impact of such therapies on vaccine-induced T cell responses.

METHODS. We longitudinally characterized humoral and Spike-specific T cell responses in inflammatory bowel disease (IBD) patients who are on antimetabolite therapy (azathioprine or methotrexate), TNF inhibitors and/or other biologic treatment (anti-integrin or anti-p40) for up to 6 months after completing two-dose COVID-19 mRNA vaccination.

RESULTS. We demonstrated that a Spike-specific T cell response is not only induced in treated IBD patients at levels similar to healthy individuals, but also sustained at higher magnitude for up to 6 months after vaccination, particularly in those treated with TNF inhibitor therapy. Furthermore, the Spike-specific T cell response in these patients is mainly preserved against mutations present in SARS-CoV-2 B.1.1.529 (Omicron) and characterized by a Th1/IL-10 cytokine profile.

CONCLUSION. Despite the humoral response defects, patients under immune-modifying therapies demonstrated a favorable profile of vaccine-induced T cell responses that might still provide a layer of COVID-19 protection.

FUNDING. This study was funded by the National Centre for Infectious Diseases NCID Catalyst Grant (FY2021ES) and the National Research Fund Competitive Research Programme (NRF-CRP25-2020-0003). The funders played no role in the design, conduct, or reporting of this study.

Favorable vaccine-induced SARS-CoV-2 specific T cell response profile in patients undergoing immune-modifying therapies

Martin Qui,¹ Nina Le Bert,¹ Webber Pak Wo Chan,² Malcolm Tan,² Shou Kit Hang,¹ Smrithi Hariharaputran,¹ Jean Xiang Ying Sim,³ Jenny Guek Hong Low,³ Weiling Ng,⁴ Wei Yee Wan,⁴ Tiing Leong Ang,⁵ Antonio Bertoletti,¹ and Ennaliza Salazar²

Article tools

Metrics

Go to

Favorable vaccine-induced SARS-CoV-2 specific T cell response profile in patients undergoing immune-modifying therapies

Martin Qui,1 Nina Le Bert,1 Webber Pak Wo Chan,2 Malcolm Tan,2 Shou Kit Hang,1 Smrithi Hariharaputran,1 Jean Xiang Ying Sim,3 Jenny Guek Hong Low,3 Weiling Ng,4 Wei Yee Wan,4 Tiing Leong Ang,5 Antonio Bertoletti,1 and Ennaliza Salazar2

Article tools

Metrics

Go to

Sign up for email alerts

Martin Qui,¹ Nina Le Bert,¹ Webber Pak Wo Chan,² Malcolm Tan,² Shou Kit Hang,¹ Smrithi Hariharaputran,¹ Jean Xiang Ying Sim,³ Jenny Guek Hong Low,³ Weiling Ng,⁴ Wei Yee Wan,⁴ Tiing Leong Ang,⁵ Antonio Bertoletti,¹ and Ennaliza Salazar²